Identification and characterization of a novel Sso7d scaffold-based binder against Notch1

[1]  Brian R. McNaughton,et al.  Minimalist Antibodies and Mimetics: An Update and Recent Applications , 2016, Chembiochem : a European journal of chemical biology.

[2]  Raja R Srinivas,et al.  Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library* , 2016, The Journal of Biological Chemistry.

[3]  S. Bray.  Notch signalling in context , 2016, Nature Reviews Molecular Cell Biology.

[4]  Kevin B Carlin.  Engineering Multivalent Protein Affinity Ligands using the Sso7d Scaffold. , 2016 .

[5]  D. Scott,et al.  Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.

[6]  M. Schmitt,et al.  Phage display selection of tight specific binding variants from a hyperthermostable Sso7d scaffold protein library , 2016, The FEBS journal.

[7]  M. Kitagawa.  Notch signalling in the nucleus: roles of Mastermind-like (MAML) transcriptional coactivators. , 2015, Journal of biochemistry.

[8]  K. Garcia,et al.  Abstract B068: Structural basis for Notch1 engagement of Delta-like 4 and Jagged1 , 2016 .

[9]  I. Weissman,et al.  Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.

[10]  Tri Giang Phan,et al.  Challenges and opportunities for non-antibody scaffold drugs. , 2015, Drug discovery today.

[11]  Richard Nicoletti,et al.  23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity , 2015, Molecular Cancer Therapeutics.

[12]  M. Fischer,et al.  Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency , 2015, Clinical Cancer Research.

[13]  K. Garcia,et al.  Structural basis for Notch1 engagement of Delta-like 4 , 2015, Science.

[14]  S. Jacobs,et al.  Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions. , 2014, Protein engineering, design & selection : PEDS.

[15]  S. Gambhir,et al.  A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma , 2013, Clinical Cancer Research.

[16]  Scott Banta,et al.  Replacing antibodies: engineering new binding proteins. , 2013, Annual review of biomedical engineering.

[17]  J. Aster,et al.  Intrinsic Selectivity of Notch 1 for Delta-like 4 Over Delta-like 1* , 2013, The Journal of Biological Chemistry.

[18]  Nimish Gera,et al.  Protein selection using yeast surface display. , 2013, Methods.

[19]  N. Perrimon,et al.  PAPTi: A Peptide Aptamer Interference Toolkit for Perturbation of Protein-Protein Interaction Networks , 2013, Scientific Reports.

[20]  A. Rangarajan,et al.  Antibodies against the extracellular domain of human Notch1 receptor reveal the critical role of epidermal-growth-factor-like repeats 25-26 in ligand binding and receptor activation. , 2013, The Biochemical journal.

[21]  Hao Wang,et al.  A Mutation in EGF Repeat-8 of Notch Discriminates Between Serrate/Jagged and Delta Family Ligands , 2012, Science.

[22]  J. Elborn,et al.  Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[23]  Y. Miki,et al.  Reduction of NOTCH1 expression pertains to maturation abnormalities of keratinocytes in squamous neoplasms , 2012, Laboratory Investigation.

[24]  A. Rangarajan,et al.  A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like Cells , 2011, Molecular Cancer Therapeutics.

[25]  R. C. Wright,et al.  Highly stable binding proteins derived from the hyperthermophilic Sso7d scaffold. , 2011, Journal of molecular biology.

[26]  V. Tolmachev,et al.  Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. , 2011, International journal of oncology.

[27]  S. Ivy,et al.  Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.

[28]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[29]  Joachim Feldwisch,et al.  Design of an optimized scaffold for affibody molecules. , 2010, Journal of molecular biology.

[30]  Deepa Subramanyam,et al.  Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis , 2009, Molecular Cancer.

[31]  M. Vidal,et al.  Edgetic perturbation of a C. elegans BCL2 ortholog , 2009, Nature Methods.

[32]  Raphael Kopan,et al.  The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.

[33]  H. Binz,et al.  DARPins: a new generation of protein therapeutics. , 2008, Drug discovery today.

[34]  P. Handford,et al.  A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition , 2008, Nature Structural &Molecular Biology.

[35]  P. Alzari,et al.  Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD , 2007, Proceedings of the National Academy of Sciences.

[36]  Eleni Bazigou,et al.  Cell signaling and cancer , 2007, Genome Biology.

[37]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[38]  K. Sakamoto,et al.  Distinct roles of EGF repeats for the Notch signaling system. , 2005, Experimental cell research.

[39]  A. McMichael,et al.  Structural and functional properties of the human notch-1 ligand binding region. , 2004, Structure.

[40]  P. B. Vander Horn,et al.  A novel strategy to engineer DNA polymerases for enhanced processivity and improved performance in vitro. , 2004, Nucleic acids research.

[41]  J. Aster,et al.  Notch Signaling in Cancer , 2002, Cancer biology & therapy.

[42]  Y. Yazaki,et al.  Mouse Jagged1 Physically Interacts with Notch2 and Other Notch Receptors , 1999, The Journal of Biological Chemistry.

[43]  J. Boulter,et al.  Jagged: A mammalian ligand that activates notch1 , 1995, Cell.

[44]  S. Knapp,et al.  Solution structure and DNA-binding properties of a thermostable protein from the archaeon Sulfolobus solfataricus , 1994, Nature Structural Biology.